Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commercialization Deal

09/17/2021 EDT

Arctic Vision announced that it will expand its exclusive license agreement with Eyenovia, Inc. to include a third asset, MydCombi™, for development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. MydCombi™ (Arctic Vision's project code ARVN004) is Eyenovia's proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for mydriasis (pupil dilation). MydCombi™ was developed leveraging the Optejet® dispenser, Eyenovia's proprietary microdose array print (MAP™) formulation and delivery platform, to ensure consistent and easy application of two mydriatic medications in a quick, high-precision, and touchless, micro-mist application. Pharmacologic mydriasis (pupil dilation) is part of the comprehensive eye exam, and is essential for diabetic retinopathy, glaucoma and retina disease screening. In two completed Phase III pivotal trials with MydCombi™, approximately 94% of treated eyes achieved rapid, sustained, and clinically significant mydriasis post-installation, and less than 1% of subjects reported stinging as an adverse event[1]. In the U.S., the New Drug Application (NDA) for MydCombi™ has been accepted for filing by the Food and Drug Administration (FDA) with PDUFA date scheduled for October 28th, 2021.


© S&P Capital IQ 2021
All news about EYENOVIA, INC.
10/25EYENOVIA : Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product b..
PU
10/25EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
AQ
10/25NASDAQ 100 : Top Midday Decliners
MT
10/25EYENOVIA : FDA Reclassifies Eyenovia's MydCombi as Drug-Device Combination Product
MT
10/25EYENOVIA : Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product b..
AQ
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commerci..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
CI
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 4,82 M - -
Net income 2021 -21,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,11x
Yield 2021 -
Capitalization 104 M 104 M -
Capi. / Sales 2021 21,6x
Capi. / Sales 2022 17,3x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,02 $
Average target price 14,67 $
Spread / Average Target 265%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-33.66%104
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158